discriminative

Bisindolylmaleimide IV is a protein kinase C (PKC) cell permeable inhibitor( IC50 : 0.10 - 0.55 μM)

6-APDB is a monoamine neurotransmitter releaser and monoamine transporter (Monoamine Transporter) modulator that selectively affects human monoamine transporters and partially agonizes the 5-HT2 receptor family. Its IC50 and Ki values for NET are 0.56 μM and 18 μM, respectively; for SERT, IC50 is 2.3 μM and Ki is 23 μM; and for DAT, IC50 is 33 μM and Ki is greater than 30 μM. In terms of rat and mouse TAAR1, 6-APDB exhibits Ki values of 1.0 μM and 0.21 μM, respectively. The compound inhibits norepinephrine and 5-HT reuptake and facilitates the release of three monoamine neurotransmitters, resulting in dose-dependent bidirectional locomotor effects in mice and complete substitution for the discriminative stimulus effects of MDMA. At high concentrations, 6-APDB shows no significant cytotoxicity and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behaviors linked to sporadic misuse.

Dihydro-β-erythroidine, a competitive nicotinic receptor antagonist, effectively blocks the discriminative stimulus properties and inhibits the anxiolytic effects induced by nicotine.